Citations

Clear

4847 citation(s) found for "Tu, Eric".

Increased Use Of Care With Retail Clinics
Furst, Joseph W. , Klavetter, Eric, Myers, Jane E., Myers, Jane

Mayo Clinic

Health Affairs | October 4, 2016 | Volume: 35 | Issue: 10 | Pages: 1935-1935

10.1377/hlthaff.2016.0936 | PMID 27702972 Get It

Safety of Intra-Articular Implantation of Oligo[Poly(ethylene glycol) Fumarate] Scaffolds into the Rabbit Knee
Ewald, Timothy J., Walker, Justin A. , Lewallen, Eric A. , Trousdale, William H. , Yaszemski, Michael J. , Hanssen, Arlen D. , Morrey, B.F. , Wijnen, André J. van , Morrey, Bernard F, van Wijnen, Andre J, Sanchez-Sotelo, Joaquin, Sánchez‐Sotelo, Joaquín , Morrey, Mark E. , Abdel, Matthew P. , van Wijnen, Andre J

Mayo Clinic

Tissue Engineering Part C: Methods | September 27, 2016 | Volume: 22 | Issue: 10 | Pages: 991-998

10.1089/ten.tec.2016.0209 | PMID 27673559 Get It

Patient Satisfaction and Quality of Life Following Surgery for Hidradenitis Suppurativa
Kohorst, John J. , Baum, Christian L. , Otley, Clark C. , Roenigk, Randall K., Pembérton, John H., Dozois, Eric J. , Tran, Nho V. , Davis, Mark D.P.

Mayo Clinic

Dermatologic Surgery | September 24, 2016 | Volume: 43 | Issue: 1 | Pages: 125-133

10.1097/dss.0000000000000942 | PMID 28027202 Get It

BACKGROUND Hidradenitis suppurativa (HS) is a progressive, recurrent inflammatory disorder. OBJECTIVE To assess long-term satisfaction and postoperative perceptions among patients who underwent surgical management of HS. MATERIALS AND METHODS A questionnaire was mailed to 499 HS surgical patients to assess surgical outcome, satisfaction, and quality of life. RESULTS Of the 499 questionnaires mailed, 113 were returned (22.6% response rate) and 2 were excluded for redundancy. Of the 111 respondents, 65 (58.6%) were female, 91 (82.0%) had Hurley Stage III disease, 88 (79.3%) were treated with excision and 23 (20.7%) with unroofing, 45 (40.5%) had perianal or perineal disease, and 41 (36.9%) had axillary disease. Most patients were satisfied or very satisfied with their surgical results (84.7%; 94 of 111), were glad they underwent surgery (96.3%; 105 of 109), and would recommend surgery to a friend or relative (82.6%; 90 of 109). Most patients were satisfied or very satisfied with the appearance of their healed wound (62.4%; 68 of 109). Retrospective mean quality of life increased significantly from 5 preoperatively to 8.4 postoperatively (p < .001). CONCLUSION Hidradenitis suppurativa surgical management was well regarded by patients and should be considered by future patients to limit the morbidity of HS.
MRI-Guided Prostate Interventions
Walser, Eric , Sze, Thaddeus F.-C., Ross, Jason R, Karamanian, Ara , Woodrum, David A.

Mayo Clinic

American Journal of Roentgenology | September 22, 2016 | Volume: 207 | Issue: 4 | Pages: 755-763

10.2214/ajr.16.16663 | PMID 30240324 Get It

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
Forman, Mark S., DeSanti, Susan, Kozauer, Nicholas, Petersen, Ronald C. , Randolph, Christopher , Isaac, Maria , Mattsson, Niklas , Bain, Lisa J. , Hendrix, James A. , Sims, John R. , Rabinovici, Gil D. , Carrillo, María C. , Miller, David S., Knopman, David S. , Smith, Eric Edward

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | September 20, 2016 | Volume: 3 | Issue: 1 | Pages: 83-91

10.1016/j.trci.2016.09.002 | PMID 29067320 Get It

Abstract Dementia is often characterized as being caused by one of several major diseases, such as Alzheimer's disease (AD), cerebrovascular disease, Lewy body disease, or a frontotemporal degeneration. Failure to acknowledge that more than one entity may be present precludes attempts to understand interactive relationships. The clinicopathological studies of dementia demonstrate that multiple pathologic processes often coexist. How overlapping pathologic findings affect the diagnosis and treatment of clinical AD and other dementia phenotypes was the topic taken up by the Alzheimer's Association's Research Roundtable in October 2014. This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies and how these issues impact clinical trials.High prevalence of multiple pathologic findings among individuals with clinical diagnosis of AD suggests that new treatment strategies may be needed to effectively treat AD and other dementing illnesses.
Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
Wang, Zhaoming , Obazee, Ofure , Jia, Jinping , Childs, Erica J., Hoskins, Jason W. , Figlioli, Gisella , Collins, Irene , Chung, Charles C., Hautman, Christopher, Arslan, Alan A. , Bracci, Paige M. , Buring, Julie E. , Gallinger, Steven , Goodman, Gary E. , Goodman, Phyllis J. , Kamineni, Aruna , Kolonel, Laurence N. , Kulke, Matthew H. , Malats, Núria , Olson, Sara H. , Sesso, Howard D. , Visvanathan, Kala , Zheng, Wei , Abnet, Christian C. , Andreotti, Gabriella , Bueno-de-Mesquita, H. Bas, Basso, Daniela , Berndt, Sonja I. , Brenner, Hermann , Burdette, Laurie , Campa, Daniele , Caporaso, Neil E. , Capurso, Gabriele , Cavestro, Giulia Martina , Costello, Eithne , Elena, Joanne W. , Boggi, Ugo , Gaziano, J. Michael , Giovannucci, Edward L. , Gross, Myron D., Haiman, Christopher A. , Hassan, Manal M. , Helzlsouer, Kathy J., Hu, Nan , Hunter, David J., Iskierka‐Jazdzewska, Elżbieta , Jenab, Mazda , Klein, Eric A. , Krogh, Vittorio , Kupčinskas, Juozas , Kurtz, Robert C. , Landi, Maria Teresa , Mambrini, Andrea , Neale, Rachel Ε. , Oberg, Ann L. , Patel, Alpa V. , Peeters, Petra H., Peters, Ulrike , Pezzilli, Raffaele , Porta, Miquel , Purdue, Mark P. , Quirós, J. Ramón , Ríboli, Elio , Rothman, Nathaniel , Scarpa, Aldo , Scélo, Ghislaine , Strobel, Oliver , Małecka‐Panas, Ewa , Tavano, Francesca , Travis, Ruth C. , Thornquist, Mark, Tjønneland, Anne , Trichopoulos, Dimitrios, Vashist, Yogesh K. , Vodička, Pavel , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Li, Donghui , Fuchs, Charles S. , Hoover, Robert N. , Hartge, Patricia, Petersen, Gloria M. , Stolzenberg-Solomon, Rachael S., Wolpin, Brian M. , Kraft, Peter , Canzian, Federico , Ámundadóttir, Laufey T. , Zhang, Mingfeng , Mocci, Evelina , Freeman, Laura E. Beane , Duell, Eric J. , Giles, Graham G. , White, Emily , Albanes, Demetrius , Brais, Lauren K , Boutron‐Ruault, Marie‐Christine , Bijlsma, Maarten F. , Cotterchio, Michelle , Gazouli, Maria , Goggins, Michael , Kaaks, Rudolf , Key, Tim , Khaw, Kay‐Tee , Kogevinas, Manolis , Kupcinskas, Juozas , Landi, Stefano , Marchand, Loı̈c Le , Männistö, Satu , Milne, Roger L. , Panico, Salvatore , Shu, Xiao‐Ou , Silverman, Debra T. , Souček, Pavel , Sund, Malin , Taylor, Philip R. , Tobias, Geoffrey S. , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Chanock, Stephen Jacob , Klein, Alison P. , Amundadottir, Laufey , Malats, Nuria , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Travis, Ruth C , Wang, Zhaoming , Abnet, Christian C , Visvanathan, Kala , Klein, Eric A , Brenner, Hermann , Strobel, Oliver , Jenab, Mazda , Kraft, Peter , Zheng, Wei , Iskierka-Jazdzewska, Elżbieta , Riboli, Elio , Vodicka, Pavel , Neale, Rachel E , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Hoskins, Jason W , Tavano, Francesca

Mayo Clinic

Oncotarget | September 16, 2016 | Volume: 7 | Issue: 41 | Pages: 66328-66343

10.18632/oncotarget.11041 | PMID 27579533 Get It

Oncologic outcomes of selective neck dissection in HPV‐related oropharyngeal squamous cell carcinoma
Zenga, Joseph , Jackson, Ryan S. , Graboyes, Evan M. , Sinha, Parul , Lindberg, Miranda, Martin, Eliot J., Rich, Jason T. , Moore, Eric J. , Haughey, Bruce H. , Ma, Daniel, Daniel, J. , Thorstad, Wade

Mayo Clinic

The Laryngoscope | September 16, 2016 | Volume: 127 | Issue: 3 | Pages: 623-630

10.1002/lary.26272 | PMID 27634021 Get It

ObjectivesTo examine outcomes of selective neck dissection (SND) in patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC) who present with clinical neck disease.Study DesignMulti‐institutional retrospective review.MethodsTwo institutional databases of patients with HPV‐related OPSCC were reviewed to identify patients with clinical (c) N1‐N3 neck disease who underwent SND ± adjuvant therapy.ResultsThree hundred and twenty‐four patients were identified with a median follow‐up of 49 months (range 3–199 months). All patients underwent transoral resection of the primary tumor and SND, including levels II–IV and ± levels I or V, with resection of additional nonlymphatic tissue (extended SND) as indicated by extent of disease, including the spinal accessory nerve (7%), the internal jugular vein (13%), and the sternocleidomastoid muscle (8%). Two hundred and seventy (83%) patients underwent adjuvant radiation. There were 13 (4%) regional recurrences and 19 (6%) distant recurrences. Regional control following salvage was 98%. On univariable analysis, absence of radiation was associated with regional recurrence (odds ratio [OR] 9.2, 95% confidence interval [CI] 2.9–29.4). On multivariable analysis, adjuvant radiation was associated with improved disease‐free survival (DFS) (OR 0.27, 95% CI 0.14–0.53) but lost significance for overall (OS) and disease‐specific survival (DSS) (P > 0.05). Five‐year Kaplan‐Meier estimates for OS, DSS, and DFS were 88% (95% CI 84%–92%), 93% (95% CI 89%–96%), and 83% (95% CI 78%–87%), respectively.ConclusionIn HPV‐related OPSCC presenting with clinical neck disease, a SND ± additional tissue resection and adjuvant therapy, when indicated, provides excellent long‐term regional control. Omission of radiotherapy increases the risk of regional recurrence, although it may not significantly impact OS or DSS. It appears unnecessary to routinely perform a comprehensive neck dissection.Level of Evidence4. Laryngoscope, 127:623–630, 2017
Variation in Hospital Risk–Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States
O’Brien, Sean M. , Rumsfeld, John S., Brennan, James M. , Shahian, David M. , Dai, David , Holmes, David R. , Hakim, Rosemarie B. , Thourani, Vinod H. , Edwards, Fred H., Douglas, Pamela S. , Brennan, J Matthew, Cohen, David Jonathan , Peterson, Eric D. , Douglas, Pamela S

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | September 14, 2016 | Volume: 9 | Issue: 5 | Pages: 560-565

10.1161/circoutcomes.116.002756 | PMID 27625404 Get It

Background— The use of transcatheter aortic valve replacement (TAVR) to treat aortic stenosis in the United States is growing, yet little is known about the variation in procedural outcomes in community practice. We developed a TAVR in-hospital mortality risk model and used it to quantify variation in mortality rates across United States (US) TAVR centers. Methods and Results— We analyzed data from 22 248 TAVR procedures performed at 318 sites participating in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (November 2011 to October 2014). A Bayesian hierarchical model was developed to estimate hospital-specific risk-adjusted mortality rates adjusting for 40 patient baseline factors. A total of 1130 in-hospital deaths (5.1%) were observed. Reliability-adjusted risk-adjusted mortality rate estimates ranged from 3.4% to 7.7% with an interquartile range of 4.8% to 5.4%. A patient’s predicted odds of dying was 80% higher if treated by a hospital 1 standard deviation above the mean compared with a hospital 1 standard deviation below the mean (odds ratio =1.8; 95% credible interval, 1.4%–2.2%). Conclusions— Risk modeling of TAVR in-hospital mortality revealed variation in risk-adjusted mortality rates during the US early commercial experience. Transcatheter Valve Therapy Registry analyses using this model will support research, feedback reporting, and the identification of factors associated with quality.
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
Yao, James C. , Pavel, Marianne, Lombard‐Bohas, Catherine , Voi, Maurizio, Brandt, Ulrike , Chen, David , Capdevila, Jaume , Vries, Elisabeth G.E. de , Tomassetti, Paola, Hobday, Timothy J. , Pommier, Rodney F. , Öberg, Kjell, van Cutsem, Eric, de Vries, Elisabeth G E, Hobday, Timothy, Pommier, Rodney, Cutsem, Eric Van , He, Wei , de Vries, Elisabeth G E

Mayo Clinic

Journal of Clinical Oncology | September 12, 2016 | Volume: 34 | Issue: 32 | Pages: 3906-3913

10.1200/jco.2016.68.0702 | PMID 27621394 Get It

Purpose Everolimus improved median progression-free survival by 6.4 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the RADIANT-3 study. Here, we present the final overall survival (OS) data and data on the impact of biomarkers on OS from the RADIANT-3 study. Methods Patients with advanced, progressive, low- or intermediate-grade pancreatic NET were randomly assigned to everolimus 10 mg/day (n = 207) or placebo (n = 203). Crossover from placebo to open-label everolimus was allowed on disease progression. Ongoing patients were unblinded after final progression-free survival analysis and could transition to open-label everolimus at the investigator’s discretion (extension phase). OS analysis was performed using a stratified log-rank test in the intent-to-treat population. The baseline levels of chromogranin A, neuron-specific enolase, and multiple soluble angiogenic biomarkers were determined and their impact on OS was explored. Results Of 410 patients who were enrolled between July 2007 and March 2014, 225 received open-label everolimus, including 172 patients (85%) randomly assigned initially to the placebo arm. Median OS was 44.0 months (95% CI, 35.6 to 51.8 months) for those randomly assigned to everolimus and 37.7 months (95% CI, 29.1 to 45.8 months) for those randomly assigned to placebo (hazard ratio, 0.94; 95% CI, 0.73 to 1.20; P = .30). Elevated baseline chromogranin A, neuron-specific enolase, placental growth factor, and soluble vascular endothelial growth factor receptor 1 levels were poor prognostic factors for OS. The most common adverse events included stomatitis, rash, and diarrhea. Conclusion Everolimus was associated with a median OS of 44 months in patients with advanced, progressive pancreatic NET, the longest OS reported in a phase III study for this population. Everolimus was associated with a survival benefit of 6.3 months, although this finding was not statistically significant. Crossover of patients likely confounded the OS results.
Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort
Leister, Erin, Coryell, Jason , Nickels, Katherine , Ryan, Nicole, Juarez‐Colunga, Elizabeth , Gaillard, William D. , Mytinger, John R. , Berg, Anne T. , Millichap, J Gordon , Nordli, Douglas R. , Joshi, Sucheta M. , Shellhaas, Renée A. , Loddenkemper, Tobias , Dlugos, Dennis , Sullivan, Joseph , Hartman, Adam L. , Kossoff, Eric H. , Grinspan, Zachary M. , Hamikawa, Lorie, Wusthoff, Courtney J. , Novotny, Edward J. , Yozawitz, Elissa , Millichap, John , Knupp, Kelly G. , Wirrell, Elaine , Shellhaas, Renée A , Novotny, Edward J , Gaillard, William D , Loddenkemper, Tobias , Yozawitz, Elissa G , Berg, Anne T , Grinspan, Zachary , Nickels, Katherine C , Coryell, Jason , Wusthoff, Courtney J

Mayo Clinic

Epilepsia | September 12, 2016 | Volume: 57 | Issue: 11 | Pages: 1834-1842

10.1111/epi.13557 | PMID 27615012 Get It

Summary Objective Infantile spasms ( IS ) represent a severe epileptic encephalopathy presenting in the first 2 years of life. Recommended first‐line therapies (hormonal therapy or vigabatrin) often fail. We evaluated response to second treatment for IS in children in whom the initial therapy failed to produce both clinical remission and electrographic resolution of hypsarhythmia and whether time to treatment was related to outcome. Methods The National Infantile Spasms Consortium established a multicenter, prospective database enrolling infants with new diagnosis of IS. Children were considered nonresponders to first treatment if there was no clinical remission or persistence of hypsarhythmia. Treatment was evaluated as hormonal therapy (adrenocorticotropic hormone [ ACTH ] or oral corticosteroids), vigabatrin, or “other.” Standard treatments (hormonal and vigabatrin) were compared to all other nonstandard treatments. We compared response rates using chi‐square tests and multivariable logistic regression models. Results One hundred eighteen infants were included from 19 centers. Overall response rate to a second treatment was 37% (n = 44). Children who received standard medications with differing mechanisms for first and second treatment had higher response rates than other sequences (27/49 [55%] vs. 17/69 [25%], p < 0.001). Children receiving first treatment within 4 weeks of IS onset had a higher response rate to second treatment than those initially treated later (36/82 [44%] vs. 8/34 [24%], p = 0.040). Significance Greater than one third of children with IS will respond to a second medication. Choosing a standard medication ( ACTH , oral corticosteroids, or vigabatrin) that has a different mechanism of action appears to be more effective. Rapid initial treatment increases the likelihood of response to the second treatment.